Pfizer Inc. PFE
30.07 USD +0.07 (+0.23%)
Nov 4, 2026, 10:14 AM EST
30.13 Day range 30.90
23.67 52-week range 30.67
- YTD
- +20.76%
- 1 year
- +23.74%
Analyst view
Consensus: buy
Buy
Price target (mean) 29.26 -2.7% downside
Now 30.07
- Target (low)
- 25.00
- Target (mean)
- 29.26
- Target (high)
- 36.00
Ratings (0m) 28 9 buy · 17 hold · 2 sell
- Strong buy1
- Buy8
- Hold17
- Sell1
- Strong sell1
Recommendation trend
- This month 28
- 1 month ago 28
- 2 months ago 28
- 3 months ago 28
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.70613 | 0.63 – 0.83 | 0.66 | +7.0% | 16.89B | -3.8% | 17 |
| Next quarter | 0.67714 | 0.54 – 0.77 | 0.75 | -9.7% | 14.02B | -3.0% | 7 |
| Current year | 2.96 | 2.88 – 3.07 | 3.22 | -8.0% | 62.23B | -0.5% | 23 |
| Next year | 2.89 | 2.52 – 3.15 | 2.96 | -2.3% | 59.89B | -3.8% | 23 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Oct 8, 2026 | Cantor Fitzgerald | Maintained | Neutral | Neutral |
| Oct 6, 2026 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Sep 10, 2026 | HSBC | Maintained | Hold | Hold |
| Aug 7, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 13, 2026 | BMO Capital | Maintained | Outperform | Outperform |
| Jul 13, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 10, 2026 | B of A Securities | Maintained | Neutral | Neutral |
| Jul 8, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Jul 6, 2026 | Cantor Fitzgerald | Reiterated | Neutral | Neutral |
| Jul 6, 2026 | HSBC | Downgrade | Buy | Hold |
| Jun 10, 2026 | RBC Capital | Upgrade | Underperform | Sector Perform |
| Apr 29, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Apr 20, 2026 | RBC Capital | Reiterated | Underperform | Underperform |
| Apr 16, 2026 | CICC | Initiated | — | Outperform |
| Apr 13, 2026 | UBS | Maintained | Neutral | Neutral |
| Apr 10, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Apr 9, 2026 | B of A Securities | Maintained | Neutral | Neutral |
| Mar 24, 2026 | Guggenheim | Maintained | Buy | Buy |
| Mar 17, 2026 | HSBC | Maintained | Buy | Buy |
| Mar 2, 2026 | Argus Research | Upgrade | Hold | Buy |
| Feb 25, 2026 | RBC Capital | Initiated | — | Underperform |
| Feb 20, 2026 | Barclays | Initiated | — | Underweight |
| Feb 9, 2026 | Freedom Broker | Maintained | Buy | Buy |
| Feb 4, 2026 | Cantor Fitzgerald | Reiterated | Neutral | Neutral |
| Jan 27, 2026 | Cantor Fitzgerald | Maintained | Neutral | Neutral |
| Dec 17, 2025 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Dec 15, 2025 | B of A Securities | Maintained | Neutral | Neutral |
| Dec 12, 2025 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Nov 24, 2025 | Guggenheim | Maintained | Buy | Buy |